Morgan Stanley Bio Line Rx Ltd. Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Morgan Stanley holds 68,437 shares of BLRX stock, worth $31,481. This represents 0.0% of its overall portfolio holdings.
Number of Shares
68,437
Previous 291,354
76.51%
Holding current value
$31,481
Previous $326,000
88.04%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
4.29MCall Options Held
49.9KPut Options Held
122K-
Alyeska Investment Group, L.P. Chicago, IL1.95MShares$898,5480.01% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$375,2144.05% of portfolio
-
Envestnet Asset Management Inc214KShares$98,3630.0% of portfolio
-
Values First Advisors, Inc.204KShares$93,7290.07% of portfolio
-
Pvg Asset Management Corp Golden, CO124KShares$56,8460.3% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $28.3M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...